Alzheimer's disease is progressive and fatal; it causes physical, psychological and economic impacts on patients and caregivers. In full growth due to the increase in life expectancy of the world population, the disease has few therapeutic options and so far no prospect of cure (WHO, 2010).
Inhibiting the enzyme Acetylcholinesterase increases the cholinergic activity of the Central Nervous System, controlling the symptoms of Alzheimer's Disease in the areas of memory and learning. The compounds developed act as inhibitors of the enzyme Acetylcholinesterase and can be used in the production of new drugs for the treatment of degenerative neuropathies, such as Alzheimer's Disease.
Agência Unesp de Inovação
Tel: +55 11 5627.0696